첨단 치료 의약품 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Advanced Therapy Medicinal Products Market size is expected to reach USD 271.06 Billion in 2034 from USD 67.21 Billion (2025) growing at a CAGR of 16.76% during 2026-2034.

The Global Advanced Therapy Medicinal Products Market is experiencing rapid growth driven by breakthroughs in gene and cell therapies. Advanced therapy medicinal products (ATMPs) include gene therapy, cell therapy, and tissue-engineered products. Increasing focus on treating rare and genetic diseases is supporting market expansion.

Major growth drivers include rising investment in biotechnology research and supportive regulatory frameworks. Pharmaceutical companies are accelerating clinical trials for innovative therapies. Growing adoption of personalized medicine approaches is further strengthening demand. Additionally, expanding collaborations between biotech firms and research institutions are fueling innovation.

Future prospects remain strong as more ATMPs receive regulatory approval and commercialization. Emerging markets investing in advanced healthcare infrastructure will create growth opportunities. Companies are focusing on scalable manufacturing and cost optimization. As regenerative medicine advances, the Global Advanced Therapy Medicinal Products Market is expected to witness sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• Cell Therapy
• Gene Therapy
• Tissue Engineering

By Indication

• Oncology
• Neurology
• Cardiology
• Dermatology
• Infectious Diseases
• Musculoskeletal Disorders
• Orthopedics
• Others (Genetic Disorders, etc.)

By End-user

• Hospitals
• Specialty Clinics
• Others (Research Institutes, etc.)

COMPANIES PROFILED

• Spark Therapeutics Inc, Bluebird Bio Inc, Novartis AG, UniQure NV, Medipost, Vericel Corporation, Pharmicell Co Ltd, Organogenesis Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Tissue Engineering Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Musculoskeletal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Orthopedics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Others (Genetic Disorders, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others (Research Institutes, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Indication
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Indication
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Indication
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Indication
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Indication
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Spark Therapeutics Inc
  • 9.2.2 Bluebird Bio Inc
  • 9.2.3 Novartis AG
  • 9.2.4 UniQure N.V
  • 9.2.5 Medipost
  • 9.2.6 Vericel Corporation
  • 9.2.7 Pharmicell Co. Ltd
  • 9.2.8 Organogenesis Inc